- herceptin.comWorldwide Rank946,696
- herceptin.comMonthly Users*00 per day*
- herceptin.comMonthly Pageviews*00 per day*
herceptin.com updated ago
Herceptin® (trastuzumab) HER2+ Breast Cancer TreatmentHerceptin (trastuzumab) is part of a treatment plan for the adjuvant treatment of patients with HER2 overexpressing, node-positive HER2+ breast cancer. Who is Herceptin for? Herceptin is approved for the adjuvant treatment of HER2-overexpressing, node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer. Herceptin can be used several different ways: As part of a treatment regimen including doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; With docetaxel and carboplatin; As a single agent following multi-modality anthracycline-based therapy. Herceptin in combination with paclitaxel is approved for the first-line treatment of HER2-overexpressing metastatic breast cancer. Herceptin as a single agent is approved for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. What important safety information should I know about Herceptin? HERCEPTIN TREATMENT CAN RESULT IN HEART PROBLEMS, INCLUDING THOSE WITHOUT SYMPTOMS (REDUCED HEART FUNCTION) AND THOSE WITH SYMPTOMS (CONGESTIVE HEART FAILURE). THE RISK AND SERIOUSNESS OF THESE HEART PROBLEMS WERE HIGHEST IN PEOPLE WHO RECEIVED BOTH HERCEPTIN AND A CERTAIN TYPE OF CHEMOTHERAPY (ANTHRACYCLINE). YOUR DOCTOR WILL STOP OR STRONGLY CONSIDER STOPPING HERCEPTIN IF YOU HAVE A SIGNIFICANT DROP IN YOUR HEART FUNCTION. You should be monitored for decreased heart function before your first dose of Herceptin, and frequently during the time you are receiving Herceptin and after your last dose of Herceptin. If you must permanently or temporarily stop Herceptin due to heart problems, you should be monitored more frequently. In one study with Herceptin and certain types of chemotherapy, an inadequate blood supply to the heart occurred. SOME PATIENTS HAVE HAD SERIOUS INFUSION REACTIONS AND LUNG PROBLEMS; FATAL INFUSION REACTIONS HAVE BEEN REPORTED. IN MOST CASES, THESE REACTIONS OCCURRED DURING OR WITHIN 24 HOURS OF RECEIVING HERCEPTIN. YOUR HERCEPTIN INFUSION SHOULD BE TEMPORARILY STOPPED IF YOU HAVE SHORTNESS OF BREATH OR VERY LOW BLOOD PRESSURE. YOUR DOCTOR WILL MONITOR YOU UNTIL THESE SYMPTOMS GO AWAY. IF YOU HAVE A SEVERE ALLERGIC REACTION, SWELLING, LUNG PROBLEMS, INFLAMMATION OF THE LUNG, OR SEVERE SHORTNESS OF BREATH, YOUR DOCTOR MAY NEED TO COMPLETELY STOP YOUR HERCEPTIN TREATMENT. Worsening of low white blood cell counts associated with chemotherapy has also occurred. Herceptin can cause low amniotic fluid levels and harm to the fetus when taken by a pregnant woman. The most common side effects associated with Herceptin were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, shortness of breath, rash, low white and red blood cells, and muscle pain. Because everyone is different, it is not possible to predict what side effects any one person will have. If you have questions or concerns about side effects, talk to your doctor. Please see the Herceptin full Prescribing Information including Boxed WARNINGS and additional important safety information on www.Herceptin.com.
herceptin.com Tags
herceptin.com is a website that ranks 946,696 in Alexa. herceptin.com is ranked 1,765,291 on statisy and has 561 backlinks according to Alexa. The Site was launched at Mar 20 1997 and its old. The hostname or fully qualified domain name (FQDN) herceptin.com is identical to the domain name herceptin.com. The domain is registered under the domain suffix com and is named herceptin. The herceptin.com Server is hosted by Genentech, Inc. and is located in United States (California). herceptin.com is not listed in the dmoz open directory project. After analyzing herceptin.com's demographics we have determined that herceptin.com average users are 55-64 years old, with Some College. We also have determined that herceptin.com's average user earns $60K - $100K a year and is most likely Female. Oh wait it seems like we know a little bit more about herceptin.com's average user, they have Children and browse from Home and are Caucasian.herceptin.com's statistics has not been updated in , update statisticsherceptin.com Statistics Icons
click a stat icon to get the code & place on your own website
herceptin.com Backlinks (561 total backlinks)
- 234
- 56
- 164
- 55
- 52
herceptin.com Usage Statistics
- Time Range Rank Reach/Mil Views/Mil Views/User Bounce Time On Site Search
- 1 month 718,261 0.00022% 0% 1.9 45.8% 2.62 58.3%
- 3 month 946,696 0.00017% 0% 1.7 54.5% 2.35 65.5%
herceptin.com Traffic by Country
- Country Rank Views % Views Users
- United States 391,194 32.5% 0 NaN
herceptin.com Keywords
Top
- 58.32% herceptin
- 1.88% her2
- 1.76% trastuzumab
- 1.03% herceptin side effects
- 0.86% genentech
- 0.82% herceptin drug
- 0.73% herceptin infusion
- 0.62% www.herceptin.com
- 0.58% herceptin genentech
- 0.58% trastuzumab herceptin
Increase
- 1.84% her2
- 1.28% her2 breast cancer
- 1.08% herceptine
- 0.87% herceptain
- 0.69% genentech patient resource center
- 0.56% metastatic breast cancer
- 0.51% herceptin patients
- 0.51% her2 cell
- 0.44% breast cancer caregivers
- 0.4% herciptin
Decrease
- 8.19% herceptin
- 0.62% www.herceptin.com
- 0.58% herceptin dosing
- 0.53% trastuzumab (herceptin)
- 0.45% herceptin breast cancer treatment
- 0.45% her2 treatment
- 0.44% genentech
- 0.42% genentech inc.
- 0.4% herceptin drug
- 0.38% genentech south sf
herceptin.com DNS Servers
- Domain Total Rank
- dnadns2e.gene.com 9 46,528
- dnadns3e.gene.com 9 46,529
- dnadns4e.gene.com 9 46,527
herceptin.com Server Info
- IP Address: 192.12.78.242
- ISP: Genentech, Inc.
- Country Name: United States
- Region: California
- City: San Francisco
- Latitude: 37.7645
- Longitude: -122.429
- Postal Code:
- Website Age: old
37.7645,-122.429herceptin.com IP info
- ISP Name IP Address ASN Registry
- Genentech, Inc. 192.12.78.242 10725 arin
herceptin.com Demographics
Age
- 18-245
- 25-34-10
- 35-34-17
- 45-542
- 55-6447
- 65+0
Education
- No College0
- Some College32
- College-8
- Graduate School-14
Income
- $0 - $30K1
- $30 - $60K5
- $60 - $100K26
- $100K+-29
Gender
- Male-36
- Female49
Has Children
- Yes9
- No-12
Browsing Location
- Home15
- School0
- Work-13
Ethnicity
- African0
- African American0
- Asian-36
- Caucasian28
- Hispanic0
- Middle Eastern0
- Other-5
herceptin.com Sites on Same ISP
- Domain PR Rank
- gene.com 7 64,001
- rituxan.com 5 1,411,402
- genentech.com 7 1,478,349
- avastin.com 5 521,089
- amdawareness.org 3 1,593,122
- herceptin.com 5 1,765,291
- tarceva.com 5 1,965,061
- researchvegf.com 4 1,983,894
- biooncology.com 6 2,004,574
- nutropin.com 0 2,027,544
- 18-24